
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 5, 2015**

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: **001-34207**

Delaware
(State or other jurisdiction
of incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02. Results of Operations and Financial Condition

On March 5, 2015, Dynavax Technologies Corporation ("Dynavax") issued a press release announcing its financial results for the year ended December 31, 2014. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

The information with respect to item 2.02 in this current report and its accompanying exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this current report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Dynavax, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibit is furnished herewith:

99.1 Press Release, dated March 5, 2015 titled, "Dynavax Reports Fourth Quarter and Year End 2014 Financial Results"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: March 5, 2015

By: /s/ DAVID JOHNSON
David Johnson
Vice President

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press Release, dated March 5, 2015 titled, "Dynavax Reports Fourth Quarter and Year End 2014 Financial Results"

DYNAVAX

INNOVATING IMMUNOLOGY

2929 Seventh Street, Suite 100
Berkeley, CA 94710

Contact:

Michael Ostrach
Chief Financial Officer
510-665-7257
mostrach@dynavax.com

DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2014 FINANCIAL RESULTS

BERKELEY, CA – March 5, 2015 – Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2014.

The Company had \$122.7 million in cash, cash equivalents and marketable securities as of December 31, 2014. Loss from operations of \$91.3 million for the year ended December 31, 2014 increased by \$24.8 million compared to the year ended December 31, 2013 primarily as a result of expenses relating to conduct of clinical trials. A Phase 3 clinical trial of hepatitis B vaccine HEPLISAV-B™ (known as HBV-23) was initiated in the second quarter of 2014 and an independent Data and Safety Monitoring Board (DSMB) reviewed available data in early November 2014 and late February 2015 and recommended continuation of the trial without change. A Phase 1/2 study of SD-101 in combination with local radiation for the treatment of indolent lymphoma was initiated in the fourth quarter.

The net loss allocable to common stockholders for the twelve months ended December 31, 2014 was \$90.7 million, or \$3.45 per basic and diluted share. The net loss allocable to common stockholders for the twelve months ended December 31, 2013 was \$75.2 million, or \$3.83 per basic and diluted share, which includes a one-time non-cash deemed dividend of \$8.5 million related to the beneficial conversion feature of the Series B Convertible Preferred Stock.

About HEPLISAV-B

HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV-B.

About SD-101

SD-101 is a proprietary, second-generation, TLR 9 agonist CpG oligodeoxynucleotide (CPG ODN). In preclinical studies, TLR 9 agonists have shown activity as monotherapy or in combination with various interventions, including immunotherapeutic and tumor-specific antibodies. SD-101 has been evaluated in two Phase 1 studies to assess its preliminary safety and tolerability.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.

– tables to follow –

DYNAVAX TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended December 31,		Years Ended December 31,	
	2014	2013	2014	2013
Revenues:				
Collaboration revenue	\$ 1,734	\$ 1,580	\$ 7,933	\$ 4,929
Grant revenue	142	1,283	2,688	5,138
Service and license revenue	401	(16)	411	1,184
Total revenues	2,277	2,847	11,032	11,251
Operating expenses:				
Research and development	19,638	12,131	84,580	50,870
General and administrative	5,052	3,700	17,377	25,943
Unoccupied facility expense	-	8	386	926
Total operating expenses	<u>24,690</u>	<u>15,839</u>	<u>102,343</u>	<u>77,739</u>
Loss from operations	(22,413)	(12,992)	(91,311)	(66,488)
Interest income	29	(47)	191	116
Interest expense	(35)	83	(35)	-
Other income (expense), net	<u>133</u>	<u>(100)</u>	<u>433</u>	<u>(348)</u>
Net loss	\$ <u>(22,286)</u>	\$ <u>(13,056)</u>	\$ <u>(90,722)</u>	\$ <u>(66,720)</u>
Preferred stock deemed dividend	-	(8,469)	-	(8,469)
Net loss allocable to common stockholders	\$ <u>(22,286)</u>	\$ <u>(21,525)</u>	\$ <u>(90,722)</u>	\$ <u>(75,189)</u>
Basic and diluted net loss per share allocable to common stockholders	\$ <u>(0.85)</u>	\$ <u>(0.91)</u>	\$ <u>(3.45)</u>	\$ <u>(3.83)</u>
Shares used to compute basic and diluted net loss per share allocable to common stockholders	<u>26,298</u>	<u>23,588</u>	<u>26,289</u>	<u>19,628</u>

DYNAVAX TECHNOLOGIES CORPORATION
SELECTED BALANCE SHEET DATA

(In thousands)
(Unaudited)

	December 31,		December 31,
	2014		2013
Assets			
Cash, cash equivalents and marketable securities	\$ 122,652	\$	189,376
Property and equipment, net	7,924		8,706
Goodwill	2,277		2,579
Other assets	<u>5,437</u>		<u>3,961</u>
Total assets	\$ <u>138,290</u>	\$	<u>204,622</u>
Liabilities and stockholders' equity			
Deferred revenues	\$ 12,765	\$	7,298
Other liabilities	15,484		11,030
Long-term debt	<u>9,559</u>		<u>-</u>
Total liabilities	37,808		18,328
Stockholders' equity	<u>100,482</u>		<u>186,294</u>
Total liabilities and stockholders' equity	\$ <u>138,290</u>	\$	<u>204,622</u>
	###		